Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Clinical trial NCT03430895 · COMPLETED

Trial details

NCT number: NCT03430895
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Transitional Cell Carcinoma of the Urothelial Tract Small Cell of the Bladder Adenocarcinoma of the Bladder Squamous Cell Carcinoma of the Bladder Metastatic Bladder Cancer

Start date: 2018-01-31
Primary completion: 2021-02-10
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.